JPRN-jRCT2031210613进行中（未招募）3 期
A Phase 3, Open-label Study to Evaluate Safety of a Booster Dose of S-268019 in Adults and Older Adults Who Have Completed COVID-19 Vaccine as a Primary Series (COVID-19)
agata Tsutae0 个研究点目标入组 150 人开始时间: 2022年2月17日最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Participant must be >= 20 years of age inclusive, at the time of signing the informed consent.
- •Participant who have received 2 doses of SARS-CoV-2 vaccine (Adults:only SPIKEVAX, Older adults: COMIRNATY or SPIKEVAX) and 6 months or more and 8 months or less after second dose.
排除标准
- •Positive SARS-CoV-2 antigen test result at Screening.
- •A known history of SARS-CoV-2 infection as determined by medical interview before study intervention.
- •Participant has a contraindication to IM injections or blood draws.
研究者
相似试验
尚未招募
3 期
An open-label, phase 3 study of the safety of the O’Neil Long Acting Naltrexone Implant treatment for substance dependenceACTRN12609000682246Go Medical Industries Inc500
进行中（未招募）
1 期
A Phase 3, Open-label Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine Followed by 23-valent Pneumococcal Polysaccharide Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant Aged 2 Years and OlderPneumococcal infectionMedDRA version: 12.0Level: LLTClassification code 10061353Term: Pneumococcal infectionEUCTR2009-012087-13-FRWyeth Research Division of Wyeth Pharmaceuticals Inc.247
进行中（未招募）
1 期
A Phase 3, Open-label Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine Followed by 23-valent Pneumococcal Polysaccharide Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant Aged 2 Years and OlderEnsayo abierto de fase 3 para evaluar la seguridad, tolerabilidad e inmunogenia de la vacuna antineumocócica conjugada tridecavalente seguida de la vacuna antineumocócica polisacárida de 23 serotipos en receptores de trasplante alogénico de células germinales hematopoyéticas de 2 o más años de edadPneumococcal infectionInfección pneumocócicaMedDRA version: 12.0Level: LLTClassification code 10061353Term: Pneumococcal infectionEUCTR2009-012087-13-ESWyeth Research Division of Wyeth Pharmaceuticals Inc.247
进行中（未招募）
不适用
3003: PH 3, HIGH RISK RECIPIENTS OF ALLOGENEIC HSCT >/= 2 YRPneumococcal infectionMedDRA version: 14.1Level: PTClassification code 10061353Term: Pneumococcal infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2009-012087-13-NLWyeth Pharmaceuticals Inc., acting through its division Wyeth Research, a Pfizer Company300
进行中（未招募）
不适用
3003: PH 3, HIGH RISK RECIPIENTS OF ALLOGENEIC HSCT >/= 2 YRPneumococcal infectionMedDRA version: 14.1Level: PTClassification code 10061353Term: Pneumococcal infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2009-012087-13-DEWyeth Research Division of Wyeth Pharmaceuticals Inc., A Pfizer Company300